atai Life Sciences (ATAI) Stock Price, News & Analysis

Company Overview

atai Life Sciences is a clinical-stage biotechnology company developing novel therapies for mental health disorders through a decentralized model of wholly owned subsidiaries and strategic collaborations. Founded in 2018 by entrepreneur Christian Angermayer, atai focuses on addressing unmet needs in conditions such as treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorders and attention-deficit/hyperactivity disorder (ADHD). The company’s approach combines psychedelic and non-psychedelic molecules alongside digital therapeutics to create differentiated treatment paradigms.

The atai pipeline features multiple proprietary programs, including a deuterated psilocybin analog designed for enhanced stability and tolerability, an intravenous synthetic DMT administered via a patented delivery system, and novel ketamine derivatives engineered to minimize dissociative side effects. In addition, atai has launched subsidiaries such as Perception Neuroscience, which focuses on nasal DMT delivery, and DemeRx, which develops treatments for addiction. These platform technologies are supplemented by biomarker development and patient-reported outcome tools aimed at optimizing clinical trial design and therapeutic impact.

Headquartered in Berlin, Germany, with research and development operations in North America and Europe, atai Life Sciences conducts global clinical trials across multiple geographies. The company entered the public markets in 2021 through a special purpose acquisition company (SPAC) merger, providing capital to advance lead programs into late-stage studies. atai leverages partnerships with academic institutions, contract research organizations and regulatory experts to streamline development pathways and support potential approvals in major markets.

Governed by founder Christian Angermayer and a leadership team drawn from established biopharma and academic backgrounds, atai Life Sciences emphasizes robust clinical evidence and regulatory compliance. The company’s scientific advisory board includes experts in psychiatry, neurology and drug delivery, reinforcing its commitment to pioneering safe, effective treatments that could transform the standard of care for patients with chronic mental health conditions.

Key Stats

• Today's Range: $5.50 to $5.70
• 50-Day Range: $3.88 to $6.45
• 52-Week Range: $1.04 to $6.75
• Volume: 4.04 million shs
• Average Volume: 6.98 million shs
• Market Capitalization: $1.30 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

atai Life Sciences Stock Analysis - MarketRank™

atai Life Sciences scored higher than 72% of companies evaluated by MarketBeat, and ranked 285th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

atai Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

atai Life Sciences has a consensus price target of $12.00, representing about 116.2% upside from its current price of $5.55.

Amount of Analyst Coverage

atai Life Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for atai Life Sciences are expected to grow in the coming year, from ($0.77) to ($0.61) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of atai Life Sciences is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of atai Life Sciences is -8.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

atai Life Sciences has a P/B Ratio of 8.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.23% of the float of atai Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

atai Life Sciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in atai Life Sciences has recently decreased by 9.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

atai Life Sciences does not currently pay a dividend.

Dividend Growth

atai Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.23% of the float of atai Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

atai Life Sciences has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in atai Life Sciences has recently decreased by 9.39%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.29

News Sentiment

atai Life Sciences has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for atai Life Sciences this week, compared to 4 articles on an average week.

Search Interest

82 people have searched for ATAI on MarketBeat in the last 30 days. This is an increase of 228% compared to the previous 30 days.

MarketBeat Follows

14 people have added atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, atai Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.80% of the stock of atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 28.41% of the stock of atai Life Sciences is held by institutions.

ATAI Stock Analysis - Frequently Asked Questions

How have ATAI shares performed this year?

atai Life Sciences' stock was trading at $1.33 at the beginning of the year. Since then, ATAI stock has increased by 317.3% and is now trading at $5.55.

How were atai Life Sciences' earnings last quarter?

atai Life Sciences N.V. (NASDAQ:ATAI) released its earnings results on Thursday, August, 14th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.02. The company had revenue of $0.72 million for the quarter.

When did atai Life Sciences IPO?

atai Life Sciences (ATAI) raised $200 million in an IPO on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers.

Who are atai Life Sciences' major shareholders?

Top institutional shareholders of atai Life Sciences include SG Americas Securities LLC (0.02%), Kingswood Wealth Advisors LLC (0.02%), Regent Peak Wealth Advisors LLC (0.01%) and Evolution Wealth Management Inc.. Insiders that own company stock include Apeiron Investment Group Ltd, Life Sciences NV Atai, Florian Brand, Anne Nagengast Johnson, Sahil Kirpekar and Srinivas Rao.
View institutional ownership trends.

How do I buy shares of atai Life Sciences?

Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of atai Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that atai Life Sciences investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/23/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ATAI
• CIK: 1420529
• Web: www.atai.net.cn
• Phone: 49-89-2153-9035
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for atai Life Sciences: $12.00
• High Price Target: $15.00
• Low Price Target: $5.00
• Potential Upside/Downside: +116.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$149.27 million
• Net Margins: N/A
• Pretax Margin: -5,180.12%
• Return on Equity: -85.43%
• Return on Assets: -64.38%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 4.02
• Quick Ratio: 4.02

Sales & Book Value

• Annual Sales: $310 thousand
• Price / Sales: 4,181.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.69 per share
• Price / Book: 8.04

Miscellaneous

• Outstanding Shares: 233,780,000
• Free Float: 171,126,000
• Market Cap: $1.30 billion
• Optionable: Optionable
• Beta: 1.58